Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-2.7%
1 month
7.46%
YTD
94.59%
1 year
71.43%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
06 September 24 |
Cleo Commences U.S. Clinical Trials
×
Cleo Commences U.S. Clinical Trials |
28 August 24 |
ASX Listing Rule 4.10.19
×
ASX Listing Rule 4.10.19 |
27 August 24 |
Appendix 4E and 2024 Annual Report
×
Appendix 4E and 2024 Annual Report |
27 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
07 August 24 |
Change of Registry Address
×
Change of Registry Address |
31 July 24 |
CLEO Selects U.S. Clinical Trial Sites
×
CLEO Selects U.S. Clinical Trial Sites |
24 July 24 |
Quarterly activities and cashflow report
×
Quarterly activities and cashflow report |
26 June 24 |
Cleo Commences US Regulatory Process with FDA
×
Cleo Commences US Regulatory Process with FDA |
24 June 24 |
Application for quotation of securities - COV
×
Application for quotation of securities - COV |
14 June 24 |
Restricted securities to be released from escrow
×
Restricted securities to be released from escrow |
29 May 24 |
COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
×
COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark |
29 April 24 |
Quarterly activities and cashflow report
×
Quarterly activities and cashflow report |
11 April 24 |
COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
×
COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials |
02 April 24 |
CLEO Appoints Partner to Commence U.S. Market Access Program
×
CLEO Appoints Partner to Commence U.S. Market Access Program |
25 March 24 |
Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
×
Peer-Review Supports CLEOs Ovarian Cancer Detection Tech |
29 February 24 |
Appendix 4D and Half Yearly Accounts
×
Appendix 4D and Half Yearly Accounts |
20 February 24 |
Corporate Presentation February 2024
×
Corporate Presentation February 2024 |
12 February 24 |
Cleo Completes Design Transfer
×
Cleo Completes Design Transfer |
31 January 24 |
Quarterly activities and cashflow report
×
Quarterly activities and cashflow report |
22 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
06 November 23 |
Completion of First Triage Test Clinical Validation Study
×
Completion of First Triage Test Clinical Validation Study |
06 November 23 |
Application for quotation of securities - COV
×
Application for quotation of securities - COV |
03 November 23 |
Pause in Trading
×
Pause in Trading |
03 November 23 |
Trading Halt
×
Trading Halt |
30 October 23 |
Quarterly activities and cashflow report
×
Quarterly activities and cashflow report |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.